Avenue Therapeutics (ATXI) Q1 2026 earnings summary

Executive summary

• Focused on developing therapies for neurologic diseases, with lead candidates ATX-04 for Pompe disease and IV tramadol for post-operative pain.

• Net loss for Q1 2026 was $0.7 million, a significant improvement from $1.9 million in Q1 2025, driven by lower R&D and G&A expenses.

• Accumulated deficit reached $106.2 million as of March 31, 2026.

• No revenue generated; operations funded primarily through equity offerings.

Financial highlights

• Cash and cash equivalents were $2.4 million at March 31, 2026, down from $2.9 million at year-end 2025.

• Operating expenses decreased 63% year-over-year to $0.7 million, with R&D at $0.2 million and G&A at $0.5 million.

• Net loss per share improved to $(0.21) from $(0.62) year-over-year.

• No financing activities in Q1 2026; prior year included $2.1 million from ATM equity sales.

Outlook and guidance

• Expects continued operating losses as product development progresses.

• Additional capital required to fund pivotal studies and ongoing operations; current cash not sufficient for 12 months.

• Evaluating feasibility and financing for a Phase 3 safety study of IV tramadol.